DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tremelimumab is an investigational drug.
There have been 136 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.
There are fifty-two US patents protecting this investigational drug and nine hundred and ninety-four international patents.
Recent Clinical Trials for Tremelimumab
|Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer||National Cancer Institute (NCI)||Phase 2|
|TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer||AstraZeneca||Phase 1|
|TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer||Daniel George, MD||Phase 1|
Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tremelimumab||Start Trial||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Start Trial|
|Tremelimumab||Start Trial||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||Start Trial|
|Tremelimumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Tremelimumab||Start Trial||Methods of using OX40 ligand encoding polynucleotides||ModernaTX, Inc. (Cambridge, MA)||Start Trial|
|Tremelimumab||Start Trial||Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|